Progression of Coronary Artery Disease During Long-term Follow-up of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II)

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Jun 1

PMID 20513067

Citations 15

Authors

Andreas W Schoenenberger

Peiman Jamshidi

Richard Kobza

Michel Zuber

Andreas E Stuck

Matthias Pfisterer

Paul Erne

Affiliations

Soon will be listed here.

Abstract

Background: This study evaluates cardiovascular risk factors associated with progression of coronary artery disease (CAD) in patients with silent ischemia following myocardial infarction.

Hypothesis: Coronary artery disease only progresses slowly with comprehensive risk factor intervention.

Methods: A total of 104 of 201 patients (51.7%) of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II) with baseline and follow-up coronary angiography were included. All patients received comprehensive cardiovascular risk factor intervention according to study protocol. Logistic regression was used to evaluate associations between baseline cardiovascular risk factors and CAD progression.

Results: The mean duration of follow-up was 10.3+/-2.4 years. At baseline, 77.9% of patients were smokers, 45.2% had hypertension, 73.1% had dyslipidemia, 7.7% had diabetes, and 48.1% had a family history of CAD. At last follow-up, only 27 patients of the initial 81 smokers still smoked, only 2.1% of the patients had uncontrolled hypertension, 10.6% of the patients had uncontrolled dyslipidemia, and 2.1% of the patients had uncontrolled diabetes. Coronary artery disease progression was found in up to 81 (77.9%) patients. Baseline diabetes and younger age were associated with increased odds of CAD progression. The time interval between baseline and follow-up angiography was also associated with CAD progression.

Conclusion: Coronary artery disease progression was highly prevalent in these patients despite comprehensive risk factor intervention. Further research is needed to optimize treatment of known risk factors and to identify other unknown and potentially modifiable risk factors.

Citing Articles

Development and Validation of a Risk Nomogram Model for Predicting Revascularization After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.

Xiao S, Zhang L, Wu Q, Hu Y, Wang X, Pan Q Clin Interv Aging. 2021; 16:1541-1553.

PMID: 34447245 PMC: 8384150. DOI: 10.2147/CIA.S325385.

Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Berezin A, Berezin A Dis Markers. 2020; 2020:1215802.

PMID: 32626540 PMC: 7306098. DOI: 10.1155/2020/1215802.

Canonical Correlation between Behavioral-Psychological Variables and Predictors of Coronary Artery Disease Prognosis.

Kim C, Noh I, Ryu J, Bae E, Cho H, Kim M Int J Environ Res Public Health. 2020; 17(5).

PMID: 32131511 PMC: 7084809. DOI: 10.3390/ijerph17051608.

Successful revascularization versus medical therapy in diabetic patients with stable right coronary artery chronic total occlusion: a retrospective cohort study.

Yan Y, Zhang M, Yuan F, Liu H, Wu D, Fan Y Cardiovasc Diabetol. 2019; 18(1):108.

PMID: 31434572 PMC: 6702731. DOI: 10.1186/s12933-019-0911-4.

Predictors of Coronary Artery Disease Progression among High-risk Patients with Recurrent Symptoms.

Farah I, Ahmed A, Odeh R, Alameen E, Al-Khateeb M, Fadel E Heart Views. 2018; 19(2):45-48.

PMID: 30505393 PMC: 6219279. DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_23_17.

References

Moise A, Theroux P, Taeymans Y, Waters D, LEsperance J, Fines P . Clinical and angiographic factors associated with progression of coronary artery disease. J Am Coll Cardiol. 1984; 3(3):659-67. DOI: 10.1016/s0735-1097(84)80240-5. View

Kronmal R, McClelland R, Detrano R, Shea S, Lima J, Cushman M . Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007; 115(21):2722-30. DOI: 10.1161/CIRCULATIONAHA.106.674143. View

Gitt A, Juenger C, Jannowitz C, Karmann B, Senges J, Bestehorn K . Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil. 2009; 16(4):438-44. DOI: 10.1097/HJR.0b013e32832a4e25. View

Thaulow E, Erikssen J, Sandvik L, Erikssen G, Jorgensen L, Cohn P . Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study). Am J Cardiol. 1993; 72(9):629-33. DOI: 10.1016/0002-9149(93)90875-d. View

Alderman E, Corley S, Fisher L, Chaitman B, Faxon D, Foster E . Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol. 1993; 22(4):1141-54. DOI: 10.1016/0735-1097(93)90429-5. View

Kramer J, Matsuda Y, Mulligan J, Aronow M, Proudfit W . Progression of coronary atherosclerosis. Circulation. 1981; 63(3):519-26. DOI: 10.1161/01.cir.63.3.519. View

Schoenenberger A, Radovanovic D, Stauffer J, Windecker S, Urban P, Eberli F . Age-related differences in the use of guideline-recommended medical and interventional therapies for acute coronary syndromes: a cohort study. J Am Geriatr Soc. 2008; 56(3):510-6. DOI: 10.1111/j.1532-5415.2007.01589.x. View

Saely C, Drexel H, Sourij H, Aczel S, Jahnel H, Zweiker R . Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: an angiographic study. Atherosclerosis. 2008; 199(2):317-22. DOI: 10.1016/j.atherosclerosis.2007.11.020. View

Haskell W, Alderman E, Fair J, Maron D, Mackey S, Superko H . Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994; 89(3):975-90. DOI: 10.1161/01.cir.89.3.975. View

10.

Palmeri S, Akula D, Agarwal S, Wilson A, Casazza L, Moreyra A . Late angiographic follow-up in adults with initial angiographic normal or minimally narrowed coronary arteries. Am J Cardiol. 2007; 99(10):1374-7. DOI: 10.1016/j.amjcard.2006.12.061. View

11.

Moise A, Theroux P, Taeymans Y, Waters D . Factors associated with progression of coronary artery disease in patients with normal or minimally narrowed coronary arteries. Am J Cardiol. 1985; 56(1):30-4. DOI: 10.1016/0002-9149(85)90561-2. View

12.

Conti C . Why we should attempt to eliminate (silent and symptomatic) ischemia in patients with chronic stable angina. Clin Cardiol. 1998; 21(12 Suppl 2):II8-11. View

13.

Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D . Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2007; 197(2):710-7. DOI: 10.1016/j.atherosclerosis.2007.07.004. View

14.

Schoenenberger A, Erne P, Ammann S, Perrig M, Burgi U, Stuck A . Prediction of hypertensive crisis based on average, variability and approximate entropy of 24-h ambulatory blood pressure monitoring. J Hum Hypertens. 2007; 22(1):32-7. DOI: 10.1038/sj.jhh.1002263. View

15.

Ryan T, Antman E, Brooks N, Califf R, Hillis L, Hiratzka L . 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.... Circulation. 1999; 100(9):1016-30. DOI: 10.1161/01.cir.100.9.1016. View

16.

Schoenenberger A, Jamshidi P, Zuber M, Stuck A, Pfisterer M, Erne P . Coronary artery disease is common in asymptomatic patients with signs of myocardial ischemia. Eur J Intern Med. 2009; 20(6):607-10. DOI: 10.1016/j.ejim.2009.04.001. View

17.

Erne P, Schoenenberger A, Burckhardt D, Zuber M, Kiowski W, Buser P . Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007; 297(18):1985-91. DOI: 10.1001/jama.297.18.1985. View

18.

Erne P, Schoenenberger A, Zuber M, Burckhardt D, Kiowski W, Dubach P . Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study. Eur Heart J. 2007; 28(17):2110-7. DOI: 10.1093/eurheartj/ehm273. View

19.

Braunwald E, Antman E, Beasley J, Califf R, Cheitlin M, Hochman J . ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on.... Circulation. 2000; 102(10):1193-209. DOI: 10.1161/01.cir.102.10.1193. View

20.

Schoenenberger A, Kobza R, Jamshidi P, Zuber M, Abbate A, Stuck A . Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). Am J Cardiol. 2009; 104(2):158-63. DOI: 10.1016/j.amjcard.2009.03.019. View